Keto diet for acromegaly
Part of Brain & nervous system, Cancer, Hormones & metabolism clinical trials.
This trial tests if a ketogenic (very low-carb) diet can help lower IGF-I levels in people with acromegaly who are already on stable medication. If you have acromegaly and your IGF-I levels are still above normal despite treatment, this diet might offer an additional way to manage your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have acromegaly from a pituitary tumor, with elevated GH and/or IGF-I levels
- Your IGF-I level is above 80% of the upper limit of normal while on a stable medication dose for at least 4 months
- You are willing and able to follow a ketogenic diet
- You are not pregnant or breastfeeding, and you have not had pituitary surgery or radiotherapy in the last 6 months
- You do not have epilepsy, are not taking the drug pegvisomant, and do not have poorly controlled diabetes (HbA1c above 6.5%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a low-carbohydrate ketogenic diet can help manage high blood sugar caused by the medication pasireotide, which is used to treat acromegaly. If you are being considered for or already taking pasireotide and your blood sugar is rising, this diet might help you avoid or reduce the need for diabetes medications.
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
This trial compares two types of radiation therapy for pituitary tumors that are still making too much hormone after surgery. It aims to see if proton beam therapy can control hormones better than standard radiation with fewer side effects.
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
This study tests a new drug called MAR002 to treat acromegaly, a hormone disorder caused by a pituitary tumor that makes too much growth hormone. The drug is designed to help lower hormone levels and improve symptoms.
This trial tests a new medication, Debio 4126, for people with acromegaly who are already being treated with octreotide or lanreotide. The goal is to see if it can help control hormone levels and is safe to use.
Hear when a new Acromegaly Due to Pituitary Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.